Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Tuesday's Health Winners & Losers

Trial results depleted DepoMed (DEPO) shares Tuesday, while other biotech stocks moved on varied news.

DepoMed gave up 60% after announcing that a phase III trial for Gabapentin GR, an investigative extended-release tablet for neuropathic pain, didn't meet its endpoint. The stock fell $2.93, to $2.00.

DepoMed tugged at the Nasdaq Biotechnology index, which was down 3.69, or 0.45, to 811.

Pained less severely, SonoSite (SONO), fell $2.25, or 6.5%, to $32.34. The company, which develops and manufactures hand-carried ultrasound systems, said it plans to offer $150 million convertible senior notes due 2014. It will grant underwriters a 30-day option to purchase $22.5 million more to cover overallotments.

SonoSite said it will use the proceeds to fund acquisitions and for general corporate purposes, and it may use a portion of the proceeds to enter into a convertible note hedge transaction with an affiliate of one of the underwriters, which would cover 67% of the notes converted.

On the winning end Tuesday, Kensey Nash (KNSY) benefited from cutting its losses. The company said it will end all activities on its embolic protection, or blood-clot prevention, platform, including a clinical trial for ProGuard. It's doing so in response to the changing market, to reduce costs and to allow its sales force to focus on its thrombectomy and chronic total occlusion platforms to surgically remove blood clots and clear blocked arteries.

The medical technology company said it won't relaunch its TriActiv FX line in the U.S. and will stop offering the TriActiv ProGuard System in Europe. As a result, Kensey Nash expects ongoing savings of $3.6 million annually, or 20 cents a share. Kensey Nash rose $1.08, or 4%, to $28.41.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,475.71 88.13 0.57%
NASDAQ 3,513.14 11.02 0.31%
S&P 500 1,678.26 9.10 0.55%
US 10 Yr 2.019% +0.075

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs